At a glance
- Originator Organon
- Class Anaesthetics; Small molecules
- Mechanism of Action Hyperpolarisation activated cation channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anaesthesia
Most Recent Events
- 20 Oct 2009 Discontinued - Phase-I for Anaesthesia in USA (PO)
- 19 Nov 2007 Organon has been acquired by Schering-Plough